[go: up one dir, main page]

AR070911A1 - Uso de antagonistas del receptor par2 activado con proteasa - Google Patents

Uso de antagonistas del receptor par2 activado con proteasa

Info

Publication number
AR070911A1
AR070911A1 ARP090100937A ARP090100937A AR070911A1 AR 070911 A1 AR070911 A1 AR 070911A1 AR P090100937 A ARP090100937 A AR P090100937A AR P090100937 A ARP090100937 A AR P090100937A AR 070911 A1 AR070911 A1 AR 070911A1
Authority
AR
Argentina
Prior art keywords
pain
par2
antagonist
fracture
inhibitor
Prior art date
Application number
ARP090100937A
Other languages
English (en)
Spanish (es)
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of AR070911A1 publication Critical patent/AR070911A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ARP090100937A 2008-03-19 2009-03-16 Uso de antagonistas del receptor par2 activado con proteasa AR070911A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3790808P 2008-03-19 2008-03-19
US11915508P 2008-12-02 2008-12-02

Publications (1)

Publication Number Publication Date
AR070911A1 true AR070911A1 (es) 2010-05-12

Family

ID=40718925

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090100937A AR070911A1 (es) 2008-03-19 2009-03-16 Uso de antagonistas del receptor par2 activado con proteasa

Country Status (6)

Country Link
AR (1) AR070911A1 (zh)
CL (1) CL2009000660A1 (zh)
PE (1) PE20091693A1 (zh)
TW (1) TW201002345A (zh)
UY (1) UY31723A (zh)
WO (1) WO2009117481A1 (zh)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7214655B2 (en) * 2001-05-21 2007-05-08 Johnson & Johnson Consumer Companies, Inc. Peptides and the use thereof in darkening the skin
US7888482B2 (en) 2006-02-10 2011-02-15 Amgen Inc. Antibodies that bind PAR-2
JO3246B1 (ar) 2009-09-09 2018-03-08 Regeneron Pharma اجسام مضادة بشرية ذات ألفة تفاعل عالية مع مستقبل 2 المفعل بالبروتين البشري
US9333152B2 (en) 2011-11-04 2016-05-10 Lipotec, S.A. Peptides which inhibit activated receptors and their use in cosmetic or pharmaceutical compositions
EP3049418A1 (en) 2013-09-25 2016-08-03 Vertex Pharmaceuticals Incorporated Imidazopyridazines useful as inhibitors of the par-2 signaling pathway
US20160000791A1 (en) 2014-07-07 2016-01-07 Mayo Foundation For Medical Education And Research Par1 modulation to alter myelination
US20190298743A1 (en) * 2016-05-20 2019-10-03 Takeda Pharmaceutical Company Limited Treatment of pain
US20190201454A1 (en) * 2016-06-23 2019-07-04 Mayo Foundation For Medical Education And Research Par2 modulation to alter myelination
CR20190417A (es) 2017-03-16 2019-12-06 Medimmune Ltd Anticuerpos anti-par2 y usos de los mismos referencia cruzada a solicitudes relacionadas

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996023225A1 (en) * 1995-01-25 1996-08-01 Cor Therapeutics, Inc. Recombinant c140 receptor, its agonists and antagonists, and nucleic acids encoding the receptor
US5629174A (en) * 1993-07-26 1997-05-13 Cor Therapeutics, Inc. Recombinant C140 receptor
US20090035315A1 (en) * 2004-06-17 2009-02-05 Stephan Christgau Method of Improving Treatments in Rheumatic and Arthritic Diseases

Also Published As

Publication number Publication date
CL2009000660A1 (es) 2010-04-16
PE20091693A1 (es) 2009-11-16
TW201002345A (en) 2010-01-16
WO2009117481A1 (en) 2009-09-24
UY31723A (es) 2009-11-10

Similar Documents

Publication Publication Date Title
AR070911A1 (es) Uso de antagonistas del receptor par2 activado con proteasa
Yang et al. Autologous interleukin-1 receptor antagonist improves function and symptoms in osteoarthritis when compared to placebo in a prospective randomized controlled trial
Bigoni et al. Acute and late changes in intraarticular cytokine levels following anterior cruciate ligament injury
Adami et al. Denosumab treatment in postmenopausal women with osteoporosis does not interfere with fracture-healing: results from the FREEDOM trial
Grossman Lupus arthritis
Ominsky et al. Inhibition of sclerostin by monoclonal antibody enhances bone healing and improves bone density and strength of nonfractured bones
Ong et al. Hyaluronic acid injections in medicare knee osteoarthritis patients are associated with longer time to knee arthroplasty
PE20240913A1 (es) Anticuerpos anti-il-2r agonistas y metodos de uso
Watt et al. New drug treatments for osteoarthritis: what is on the horizon?
Chen et al. Arthrofibrosis and large joint scarring
AR081434A1 (es) Anticuerpo del peptido relacionado con el gen calcitonina (cgrp), composicion farmaceutica que lo comprende, uso de dicho anticuerpo para preparar un medicamento util para tratar dolor de osteoartritis o migranas y fragmento de union a antigeno de dicho anticuerpo
CY1118044T1 (el) Παρασκευασμα συνδυασμου με ανταγωνιστη και κορτικοστεροειδες
Trueba Davalillo et al. Clinical efficacy of intra-articular injections in knee osteoarthritis: a prospective randomized study comparing hyaluronic acid and betamethasone
CY1123240T1 (el) Αντισωμα αντι fgf23 και μια φαρμακευτικη συνθεση που το περιλαμβανει
EA200900709A1 (ru) Способы лечения хронических воспалительных заболеваний с использованием антагониста gm-csf
Tsai et al. Isorhamnetin ameliorates inflammatory responses and articular cartilage damage in the rats of monosodium iodoacetate-induced osteoarthritis
EA201070725A1 (ru) Бис-пиридилпиридоны как антагонисты рецептора 1 меланинконцентрирующего гормона
CL2011002416A1 (es) Uso de un anticuerpo anti-il 17a y/o il-17f o fragmento que une antígeno del mismo que sirve en la preparación de un medicamento para el tratamiento de un trastorno de resistencia a insulina en un mamifero; kit.
Kuswanto et al. Repurposing drugs for the treatment of osteoarthritis
CL2015000119A1 (es) El compuesto (r)-1-(1-(metil-sulfonil)-propan-2-il)-4-(trifluoro-metil)-1h-indol-5-carbonitrilo, modulador del receptor de androgeno; composicion farmaceutica; y su uso para tratar consuncion muscular asociada con epoc, con enfermedad cronica del riñon, con insuficiencia cardiaca cronica, e incontinencia urinaria, y para acelerar la reparacion y sanado de fractura de cadera.
King et al. Ketorolac and bone healing: a review of the basic science and clinical literature
y Hernandez et al. Viscosupplementation of the ankle: a prospective study with an average follow-up of 45.5 months
Altman Pharmacological therapies for osteoarthritis of the hand: a review of the evidence
Gossec et al. Do intra-articular therapies work and who will benefit most?
Sewell et al. Emerging injectable therapies for osteoarthritis

Legal Events

Date Code Title Description
FB Suspension of granting procedure